These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis. Samur S; Klebanoff M; Banken R; Pratt DS; Chapman R; Ollendorf DA; Loos AM; Corey K; Hur C; Chhatwal J Hepatology; 2017 Mar; 65(3):920-928. PubMed ID: 27906472 [TBL] [Abstract][Full Text] [Related]
6. Finding the cure for primary biliary cholangitis - Still waiting. Tanaka A; Gershwin ME Liver Int; 2017 Apr; 37(4):500-502. PubMed ID: 28371099 [TBL] [Abstract][Full Text] [Related]
7. New developments in the treatment of primary biliary cholangitis - role of obeticholic acid. Jhaveri MA; Kowdley KV Ther Clin Risk Manag; 2017; 13():1053-1060. PubMed ID: 28860789 [TBL] [Abstract][Full Text] [Related]
8. [Research progress on risk factors for poor response of ursodeoxycholic acid in primary biliary cholangitis]. Yuan Z; Jia G; Han Y Zhonghua Gan Zang Bing Za Zhi; 2019 Jan; 27(1):73-76. PubMed ID: 30685931 [TBL] [Abstract][Full Text] [Related]
9. IgM response is a prognostic biomarker of primary biliary cholangitis treated with ursodeoxycholic acid and bezafibrate. Takano K; Saeki C; Oikawa T; Hidaka A; Mizuno Y; Ishida J; Takakura K; Nakano M; Torisu Y; Amano K; Ishikawa T; Zeniya M; Tsubota A; Saruta M J Gastroenterol Hepatol; 2020 Apr; 35(4):663-672. PubMed ID: 31677185 [TBL] [Abstract][Full Text] [Related]
10. Update on New Drugs and Those in Development for the Treatment of Primary Biliary Cholangitis. Bahar R; Wong KA; Liu CH; Bowlus CL Gastroenterol Hepatol (N Y); 2018 Mar; 14(3):154-163. PubMed ID: 29928160 [TBL] [Abstract][Full Text] [Related]
15. Does antimitochondrial antibody status affect response to treatment in patients with primary biliary cirrhosis? Outcomes of ursodeoxycholic acid therapy and liver transplantation. Kim WR; Poterucha JJ; Jorgensen RA; Batts KP; Homburger HA; Dickson ER; Krom RA; Wiesner RH; Lindor KD Hepatology; 1997 Jul; 26(1):22-6. PubMed ID: 9214447 [TBL] [Abstract][Full Text] [Related]
16. [Advances in the treatment of primary biliary cholangitis]. Li YM; Wang QX; Ma X Zhonghua Gan Zang Bing Za Zhi; 2017 Nov; 25(11):805-809. PubMed ID: 29325272 [TBL] [Abstract][Full Text] [Related]
17. Bezafibrate Improves GLOBE and UK-PBC Scores and Long-Term Outcomes in Patients With Primary Biliary Cholangitis. Honda A; Tanaka A; Kaneko T; Komori A; Abe M; Inao M; Namisaki T; Hashimoto N; Kawata K; Takahashi A; Ninomiya M; Kang JH; Arakawa M; Yamagiwa S; Joshita S; Umemura T; Sato K; Kaneko A; Kikuchi K; Itakura J; Nomura T; Kakisaka K; Fujii H; Kawada N; Takikawa Y; Masaki T; Ohira H; Mochida S; Yoshiji H; Iimuro S; Matsuzaki Y; Takikawa H; Hepatology; 2019 Dec; 70(6):2035-2046. PubMed ID: 30737815 [TBL] [Abstract][Full Text] [Related]
18. RANK/RANKL Acts as a Protective Factor by Targeting Cholangiocytes in Primary Biliary Cholangitis. Hao YL; Bian ZL; Ju LL; Liu Y; Qin G Dig Dis Sci; 2020 Feb; 65(2):470-479. PubMed ID: 31377883 [TBL] [Abstract][Full Text] [Related]
19. The ursodeoxycholic acid response score predicts pathological features in primary biliary cholangitis. Kawata K; Joshita S; Shimoda S; Yamashita Y; Yamashita M; Kitsugi K; Takatori S; Ohta K; Ito J; Shimoyama S; Noritake H; Suda T; Harada K Hepatol Res; 2021 Jan; 51(1):80-89. PubMed ID: 33080094 [TBL] [Abstract][Full Text] [Related]